Search results
Showing 4171 to 4185 of 9065 results
This indicator covers the percentage of patients on the CKD register who are treated with an SGLT-2 inhibitor if they have: type 2 diabetes, or no type 2 diabetes and an eGFR 20 ml/min/1.73 m2 to 44 ml/min/1.73 m2 and are currently treated with an ACE inhibitor or angiotensin receptor blocker (ARB) (unless these are contraindicated) or an eGFR 45 ml/min/1.73 m2 to 59 ml/min/1.73 m2, are currently treated with an ACE inhibitor or ARB (unless these are contraindicated) and have a urine albumin-to-creatinine ratio (ACR) of 22.6 mg/mmol or more. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes.
Embed NICE content in your digital products and services with our syndication API.
Home News Podcasts {"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"/"
Agenda and papers of the NICE public board meeting on 18 March 2026
Agenda and papers of the NICE public board meeting on 18 September 2025
Home About us Our board Public board meetings...
Home Implementing NICE guidance Social care Using NICE guidance in social work: scenarios Families and relationships settings...
Home Implementing NICE guidance Social care Using NICE guidance in social work: scenarios for principle social workers Positive workplaces for social
Check to see if you're entitled to access a range of content purchased by the NHS. If you are eligible, you can register for an OpenAthens account using our online form.
Home Implementing NICE guidance Social care Using NICE guidance in social work: scenarios {"@context":"http://schema.org","@type":"BreadcrumbList"
NICE public committee meetings supports our commitment to having processes in place that are rigorous, open, and transparent.
Home Get involved...
Find out more about the types of organisations that can register to be a stakeholder at NICE.
Membership details, terms of reference, future meeting dates and past meeting minutes for our indicator advisory committee.
Our board has 2 sub-committees: the audit and risk assurance committee and the remuneration committee.